Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -27375.58% is 330% below its 5-year average of -6369.18%, near the low end of its 5-year range (-28136.69%–0.00%).
50.00% below its 12-month average of -18250.78%.
Reported quarterly EBITDA margin; no daily interpolation. Q4 FY2025 (2025-06-30): -28136.69%.
EBITDA MARGIN
-27375.58%
EBITDA MARGIN AVG TTM
-18250.78%
EBITDA MARGIN AVG 3Y
-12478.75%
EBITDA MARGIN AVG 5Y
-6369.18%
EBITDA MARGIN AVG 10Y
-1571.81%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-50.00%
CURRENT VS 3Y AVG
-119.38%
CURRENT VS 5Y AVG
-329.81%
CURRENT VS 10Y AVG
-1641.66%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Incannex Healthcare Limited
Market Cap
$38.82M
EBITDA Margin
-27375.58%
TTM Avg
-18250.78%
3Y Avg
-12478.75%
5Y Avg
-6369.18%
Market Cap
$38.60M
EBITDA Margin
6.14%
TTM Avg
3.48%
3Y Avg
3.86%
5Y Avg
5.21%
Market Cap
$37.81M
EBITDA Margin
-1929.22%
TTM Avg
-1308.49%
3Y Avg
-1783.80%
5Y Avg
-1343.37%
Market Cap
$40.28M
EBITDA Margin
-359.76%
TTM Avg
-259.71%
3Y Avg
-233.72%
5Y Avg
-2126.07%
Market Cap
$36.64M
EBITDA Margin
-6.58%
TTM Avg
-1.77%
3Y Avg
-0.14%
5Y Avg
1.64%
Market Cap
$36.32M
EBITDA Margin
-136.01%
TTM Avg
-1016.71%
3Y Avg
-1237.80%
5Y Avg
-1237.80%
Market Cap
$35.82M
EBITDA Margin
-127.12%
TTM Avg
-129.61%
3Y Avg
-125.08%
5Y Avg
-93.97%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Incannex Healthcare Limited (IXHL) | $38.82M | -27375.58% | -18250.78% | -12478.75% | -6369.18% |
| Harvard Bioscience, Inc. (HBIO)vs › | $38.60M | 6.14% | 3.48% | 3.86% | 5.21% |
| Edesa Biotech, Inc. (EDSA)vs › | $37.81M | -1929.22% | -1308.49% | -1783.80% | -1343.37% |
| Metagenomi, Inc. Common Stock (MGX)vs › | $40.28M | -359.76% | -259.71% | -233.72% | -2126.07% |
| DocGo Inc. (DCGO)vs › | $36.70M | -22.81% | -7.79% | -0.80% | -0.97% |
| Accuray Incorporated (ARAY)vs › | $36.64M | -6.58% | -1.77% | -0.14% | 1.64% |
| BriaCell Therapeutics Corp. (BCTX)vs › | $36.45M | N/A | N/A | N/A | N/A |
| Elicio Therapeutics, Inc. (ELTX)vs › | $36.32M | -136.01% | -1016.71% | -1237.80% | -1237.80% |
| Elutia Inc (ELUT)vs › | $35.82M | -127.12% | -129.61% | -125.08% | -93.97% |
| CVRx, Inc. (CVRX)vs › | $42.19M | -89.16% | -101.97% | -124.94% | -147.77% |
Gross Margin
0.0%
EBITDA Margin
-27375.6%
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2025-06-30 | -28136.69% |
| 2024-09-30 | -8364.86% |
| 2022-06-30 | -934.68% |
| 2021-06-30 | -4.81% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | -774.03% |
| 2019-09-30 | -25213.09% |
| 2019-06-30 | -125.71% |
| 2018-09-30 | -312.99% |
| 2018-06-30 | -216.85% |
| 2017-09-30 | -510.12% |
| 2017-06-30 | -612.27% |
| 2016-09-30 | -5499.85% |
| 2016-03-31 | -587.74% |
| 2015-09-30 | -2489.56% |
